Halting of Progression of CKD Stage 5 with Finerenone

Introduction: Finerenone is a non-steroidal aldosterone receptor antagonist, FDA approved to slow progression of diabetic nephropathy Case Description: A 76 year old male with CKD V, eGFR of 13 in November 2021 began treatment for diabetes with Glyburide, Losartan and Finerenone. The patient has remained well and free of need for dialysis for over 41 months. During this time his eGFR has been stable averaging 10 ml/min. Serum potassium remains normal with no treatment. Discussion: This report represents an extraordinary slowing of progression of CKD V. In the study of KU et al, (Clin J Amer Soc May 2018 Neph) the median time for patients with CKD V remaining free of dialysis was 9.6 months. Finerenone appears to be responsible for the halting of progression of CKD V in this patient.